These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26982008)

  • 1. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
    Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
    J Clin Endocrinol Metab; 2016 May; 101(5):2056-62. PubMed ID: 26982008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2003 May; 52(5):565-72. PubMed ID: 12759885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
    Tripathy D; Cobb JE; Gall W; Adam KP; George T; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Reaven PD; Musi N; Ferrannini E; DeFronzo RA
    J Clin Endocrinol Metab; 2015 May; 100(5):1855-62. PubMed ID: 25603459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
    Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
    Diabetes Care; 2014 Jun; 37(6):1706-11. PubMed ID: 24705615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.
    Defronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD;
    Diabetes; 2013 Nov; 62(11):3920-6. PubMed ID: 23863810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
    Espinoza SE; Wang CP; Tripathy D; Clement SC; Schwenke DC; Banerji MA; Bray GA; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Stentz FB; Reaven PD; DeFronzo RA; Musi N
    Age (Dordr); 2016 Dec; 38(5-6):485-493. PubMed ID: 27585671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
    Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
    Gupta AK; Smith SR; Greenway FL; Bray GA
    Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes.
    Khan M; Murray FT; Karunaratne M; Perez A
    Diabetes Obes Metab; 2006 Jan; 8(1):31-8. PubMed ID: 16367880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R; Xu Y; Abbadessa M;
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
    Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2004 Apr; 53(4):414-22. PubMed ID: 15045685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.